Approval · Notice of Compliance 37014 · 2026
GRASTOFIL: Notice of Compliance 37014
Issued February 24, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 37014
- Date
- February 24, 2026
- Company
- Apotex Inc.Toronto, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Labelling updates
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| GRASTOFIL | Not yet assigned | — |
Medicinal ingredients
- FILGRASTIM (R-METHUG-CSF) 300 MG per 5ML
- FILGRASTIM (R-METHUG-CSF) 480 MG per 0.8ML